Clinical Trials
8 trialsNCT00937937 2026-05-29
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01434316 2026-04-13
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01711528 2018-05-11
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01624441 2018-03-30
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01783171 2017-08-22
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01026324 2017-04-04
Dinaciclib in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01096342 2014-06-18
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed